CLAIMS

1. A prostaglandin derivative represented by Formula (I):



(I)

wherein X is a halogen atom in the α- or β-position, Y is an ethylene group, a vinylene group or an ethynylene group, A is a group represented by the formula: $O(CH_2)_n$, $S(O)_p(CH_2)_n$, $O(CH_2)_qO(CH_2)_r$, $O(CH_2)_qS(O)_p(CH_2)_r$, $S(O)_p(CH_2)_qS(O)_p(CH_2)_r$ or $S(O)_p(CH_2)_qO(CH_2)_r$ (wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an integer of 1 to 3, and r is 0 or 1), R^1 is a C_{3-10} cycloalkyl group, a C_{1-4} alkyl-C_{3-10} cycloalkyl group, a C_{3-10} cycloalkyl-C_{1-4} alkyl group, a C_{5-10} alkyl group, a C_{5-10} alkenyl group, a C_{5-10} alkynyl group or a bridged cyclic hydrocarbon group, R^2 is a hydrogen atom, a C_{1-10} alkyl group or a C_{3-10} cycloalkyl group, and m is 0, 1 or 2], a pharmaceutically acceptable salt thereof or a hydrate thereof.

2. The prostaglandin derivative of Formula (I) according

to Claim 1 wherein R^1 is a C_{3-10} cycloalkyl group, a C_{1-4} alkyl-C_{3-10} cycloalkyl group, a C_{3-10} cycloalkyl-C_{1-4} alkyl group, a branched C_{5-10} alkyl group, a branched C_{5-10} alkenyl group, a branched C_{5-10} alkynyl group or a bridged cyclic hydrocarbon group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

3. The prostaglandin derivative of Formula (I) according to Claim 2 wherein X is a chlorine or bromine atom in the α- or β-position, R^1 is a C_{3-10} cycloalkyl group, a C_{3-10} cycloalkyl-C_{1-4} alkyl group or a branched C_{5-10} alkenyl group, and R^2 is a hydrogen atom or a C_{1-10} alkyl group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

4. The prostaglandin derivative of Formula (I) according to any one of Claims 1 to 3 wherein is Y is a vinylene group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

5. The prostaglandin derivative of Formula (I) according to any one of Claims 1 to 3 wherein is Y is an ethynylene group; the pharmaceutically acceptable salt thereof or the hydrate thereof.

6. The prostaglandin derivative of Formula (I) according to any one of Claims 1 to 5 wherein is A is a group represented by the formula:

$S(O)_p(CH_2)_n$,

$S(O)_p(CH_2)_qS(O)_p(CH_2)_r$ or

$S(O)_p(CH_2)_qO(CH_2)_r$

(wherein n is an integer of 1 to 5, p is 0, 1 or 2, q is an

integer of 1 to 3, and r is 0 or 1); the pharmaceutically acceptable salt thereof or the hydrate thereof.

7. The prostaglandin derivative of Formula (I) according to Claim 6 wherein is p is 0; the pharmaceutically acceptable salt thereof or the hydrate thereof.

8. A pharmaceutical preparation which comprises as an effective ingredient the prostaglandin derivative according to any one of Claims 1 to 7, the pharmaceutically acceptable salt thereof or the hydrate thereof.